Takeda Pharmaceutical Co Ltd ADR TAK
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TAK is a good fit for your portfolio.
News
-
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
-
Takeda Says FDA Has Approved Subcutaneous Entyvio for Crohn's Disease
-
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
-
Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food
-
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
-
Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
-
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
-
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
Trading Information
- Previous Close Price
- $13.24
- Day Range
- $13.30–13.41
- 52-Week Range
- $13.11–17.12
- Bid/Ask
- $13.26 / $13.79
- Market Cap
- $41.92 Bil
- Volume/Avg
- 1.6 Mil / 1.8 Mil
Key Statistics
- Price/Earnings (Normalized)
- 14.01
- Price/Sales
- 1.40
- Dividend Yield (Trailing)
- 4.75%
- Dividend Yield (Forward)
- 4.82%
- Total Yield
- 4.82%
Company Profile
Takeda Pharmaceutical is Japan’s largest pharmaceutical company, with revenue of JPY 4 trillion in fiscal 2022. The company’s five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Large Core
- Total Number of Employees
- 49,095
- Website
- https://www.takeda.com
Competitors
Valuation
|
Metric
|
TAK
|
4519
|
4568
|
|---|---|---|---|
Price/Earnings (Normalized) | 14.01 | 26.83 | 40.21 |
Price/Book Value | 0.86 | 5.15 | 5.48 |
Price/Sales | 1.40 | 7.54 | 5.79 |
Price/Cash Flow | 7.28 | 30.00 | 31.38 |
Price/Earnings
TAK
4519
4568
Financial Strength
|
Metric
|
TAK
|
4519
|
4568
|
|---|---|---|---|
Quick Ratio | 0.47 | 3.68 | 2.74 |
Current Ratio | 1.04 | 4.74 | 3.49 |
Interest Coverage | 2.01 | 16,438.81 | 11.76 |
Quick Ratio
TAK
4519
4568
Profitability
|
Metric
|
TAK
|
4519
|
4568
|
|---|---|---|---|
Return on Assets (Normalized) | 2.86% | 17.64% | 7.33% |
Return on Equity (Normalized) | 6.13% | 21.60% | 13.01% |
Return on Invested Capital (Normalized) | 4.78% | 21.60% | 11.32% |
Return on Assets
TAK
4519
4568
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Qdyfgbdhk | Yqcvf | $70.0 Bil | |
MKKGY
| Merck KGaA ADR | Gkzsvbdfb | Gzrdpqf | $67.6 Bil | |
HLN
| Haleon PLC ADR | Gpdsrdfl | Yhq | $37.0 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Xmbppwqmp | Mcbqm | $14.5 Bil | |
VTRS
| Viatris Inc | Ltlpznwk | Gcwn | $13.4 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Trzsdcfl | Lqcz | $12.0 Bil | |
CTLT
| Catalent Inc | Glpvtcz | Sbsfn | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Mnfyjlc | Nrm | $4.1 Bil | |
CURLF
| Curaleaf Holdings Inc | Czzrywqbt | Mrccz | $3.6 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Sksmpkww | Dlbfr | $3.5 Bil |